Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023
ID : RND_044606 Format : PDF June, 2019 Publisher : Pages : 277
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).
This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report discusses several significant, large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.
The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments, droplet digital PCR (polymerase chain reaction), target enrichment, single-cell DNA polymerase, non-invasive prenatal testing (NIPT), fetal-cell NIPT, CTC (circulating tumor cell) capture and detection and liquid biopsy.
The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/ early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia Pacific, Rest of the World).
Market data covers 2017, 2018 and 2023 (forecasted).
More than 175 companies in the liquid biopsy industry are profiled in this report.
BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.
- 27 data tables and 70 additional tables
- An overview of the global markets for liquid biopsy technologies, applications, industry subsegments
- Analyses of global market trends with data from 2017 to 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Regional dynamics of the liquid biopsy diagnostics market covering North America, Europe, APAC and rest of the world covering other emerging economies
- Discussion of major drivers, current trends and global outlook of liquid biopsy technologies, their growth potential and factors that influence the market
- Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Comparative study of liquid biopsy with conventional biopsy technologies and coverage of their respective biomarkers
- Comprehensive company profiles of key market players within the industry, including Apocell Inc., Becton, Dickinson and Co., Clinical Genomics Technologies, Exact Sciences Corp. and Thermo Fisher Scientific Inc."
Liquid biopsy is an attractive option as a supplement or alternative to tissue biopsy for applications in reproductive health, cancer and transplant medicine. Liquid biopsy involves detecting and analyzing foreign-derived biomarkers present in body fluids such as blood or urine. The origin of the biomarker defines the liquid biopsy application: tumor (cancer applications), fetus (prenatal screening applications) or transplanted organ (transplant medicine applications).
Biomarker types of interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable detection of biomarkers that are present in fluids at very low concentrations.
Competitors clusters around each of the three applications segments: non-invasive prenatal testing (NIPT), cancer and transplant medicine. Although there is recent movement across the segments by some companies.
When compared with conventional tissue biopsy, liquid biopsy tests address a significant medical need: a biopsy that is non-invasive and has little or no risk of medical complications. The validation of this testing platform and demonstration of clinical utility first occurred in the high-risk pregnancy segment of the NIPT industry, resulting in high market penetration. Substantial progress is being made in the average-risk pregnancy NIPT market segment and in some applications in cancer and transplant medicine.
Reasons for Doing This Study
Conventional biopsy methods are often invasive, uncomfortable and carry risks of side effects. Liquid biopsy addresses these issues because it is non-invasive and carries little, if any, risks of side effects. In the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to screen, monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability and is of high interest to the medical community.
Liquid biopsy-enabling technologies are coming to the forefront and provide significant market growth momentum to the industry. Downstream analysis technologies such as next-generation sequencing (NGS) and digital PCR are progressing in capabilities, efficiency and costs. Upstream technologies such as microfluidics, cell-free DNA capture and isolation, cell capture and DNA amplification are also making significant progress.
Liquid biopsy is also gaining significant traction with key opinion leaders, medical societies and insurance payors.
As a result, liquid biopsy is penetrating into attractive clinical applications including average-risk, noninvasive prenatal testing and cancer therapy guidance and monitoring. Based on these trends, liquid biopsy markets are emerging rapidly and the need for industry and market characterization is great. The outstanding growth potential for liquid biopsy diagnostics makes it particularly timely for preparing this updated report."
"Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary
Chapter 3 Overview
Liquid Biopsy vs. Traditional Biopsy
Forces Driving Growth
Key Developments in Liquid Biopsy
Chapter 4 Technology Background
Liquid Biopsy Biomarkers
Invasive Prenatal Testing
Non-invasive Prenatal Testing (NIPT)
Circulating Tumor Cells (CTCs)
Liquid Biopsy vs. Conventional Biopsy
Chapter 5 Liquid Biopsy Initiatives
Immunomonitor Consortium (2018)
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program (2018)
Liquid Biopsies and Imaging for Improved Cancer Care (2018)
Precancer Atlas (2018)
Blood Profiling Atlas (2016)
Human Cell Atlas (2016)
Population Sequencing Projects (2016)
Precision Medicine Initiative (2015)
Early Cancer Detection Consortium (2014)
CTC Trap Consortium (2012)
Single-Cell Research (2012)
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
Worldwide Innovative Networking (WIN) Consortium (2010)
Next-Generation Single-Cell Analysis Program
Single-Cell Proteomics and Lipidomics Project
Chapter 6 Market Breakdown by End User
Cancer Biomarker Status
Cancer Market Segments
Transplant Diagnostic Applications
Chapter 7 Liquid Biopsy Industry
Advanced Sequencing Instruments Industry
NGS Instrument Industry
Third-Generation Sequencing Industry
Droplet Digital PCR Industry
Target Enrichment and Amplification Industry
Single-cell DNA Polymerase Industry
Non-Invasive Prenatal Testing Industry
Fetal Cell NIPT Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry
Chapter 8 Industry Acquisitions and Strategic Alliances
Mergers and Acquisitions
Chapter 9 Liquid Biopsy Markets
Forces Driving Growth
Liquid Biopsy Market by Application
Liquid Biopsy Market by Biomarker Type
Liquid Biopsy Market by Analysis Platform
Liquid Biopsy Market by Analysis Purpose
Non-Invasive Prenatal Testing Market
Cancer Market by Disease Indication
Cancer Market by Analysis Purpose
Cancer Market by Biomarker Class
Cancer Market by Analysis Method
Breast Cancer Market
Colorectal Cancer Market
Hematological Cancer Market
Lung Cancer Market
Regional Market Analysis
Chapter 10 Patent Review/ New Developments
Circulating Tumor Cell Patents
Cell-free DNA Patents
Liquid Biopsy and Sequencing-Related Patent Issues
Chapter 11 Company Profiles
ADAPTIVE BIOTECHNOLOGIES INC.
ADVANCED CELL DIAGNOSTICS INC.
AGILENT TECHNOLOGIES, INC.
AKADEUM LIFE SCIENCES
AMOY DIAGNOSTICS CO. LTD.
ARCEDI BIOTECH APS
BECTON, DICKINSON AND CO.
BELLWETHER BIO INC.
BERRY GENOMICS CO. LTD.
BIOCORE CO. LTD.
BIO-RAD LABORATORIES INC.
BIOVENDOR-LABORATORNI MEDICINA A.S.
BLUESTAR GENOMICS INC.
CANCER GENETICS INC.
CELL MICROSYSTEMS INC.
CLINICAL GENOMICS TECHNOLOGIES
CS GENETICS LTD.
CYGNUS BIOSCIENCES CO. LTD.
CYNVENIO BIOSYSTEMS INC.
DATAR CANCER GENETICS LTD.
DIRECT GENOMICS CO. LTD.
DNA ELECTRONICS LTD.
DOVETAIL GENOMICS LLC
EPIC SCIENCES INC.
EXACT SCIENCES CORP.
EXOSOME SCIENCES INC.
EZLIFE BIO INC.
FLUXION BIOSCIENCES INC.
GENESEQ BIOSCIENCES PTY LTD.
GENETICS RESEARCH LLC
GENOMIC HEALTH INC.
GENEXOSOME TECHNOLOGIES INC.
GUARDANT HEALTH INC.
HELIX OPCO LLC
HTG MOLECULAR DIAGNOSTICS INC.
INEX INNOVATIONS EXCHANGE PTE. LTD.
INTERPACE DIAGNOSTICS LLC
JBS SCIENCE INC.
KONINKLIJKE PHILIPS N.V.
LABORATORY CORP. OF AMERICA INC.
LEXENT BIO INC.
LUCENCE DIAGNOSTICS PTE. LTD.
MAMMOTH BIOSCIENCES INC.
MDNA LIFE SCIENCES INC.
MEDGENOME LABS PVT. LTD.
MENARINI SILICON BIOSYSTEMS SPA
MOLECULAR HEALTH GMBH
MYRIAD GENETICS INC.
NANOSTRING TECHNOLOGIES INC.
NANOVIEW BIOSCIENCES INC.
NEW ENGLAND BIOLABS
NEW ONCOLOGY GMBH
NOVOGENE CO. LTD.
NUGEN TECHNOLOGIES INC.
NX PRENATAL INC.
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PARADIGM DIAGNOSTICS INC.
PARSEQ LAB CO. LTD.
PATHWAY GENOMICS CORP.
PERSONAL GENOME DIAGNOSTICS INC.
PORTABLE GENOMICS LLC
PREMAITHA HEALTH PLC
PROVISTA DIAGNOSTICS INC.
QUANTUM BIOSYSTEMS INC.
QUEST DIAGNOSTICS INC.
REAL TIME GENOMICS INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
SEVEN BRIDGES GENOMICS INC.
SINGLERA GENOMICS INC.
SPHERE FLUIDICS LTD.
STRAND LIFE SCIENCES PVT. LTD.
STRATOS GENOMICS INC.
SYSMEX INOSTICS GMBH
TAI DIAGNOSTICS INC.
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TWO PORE GUYS INC.
TYMORA ANALYTICAL OPERATIONS LLC
UBIQUITY GENOMICS INC.
XING TECHNOLOGIES LLC
YIKON GENOMICS CO. LTD."
A research methodology is a systematic approach for assessing or conducting a market study. Researchers tend to draw on a variety of both qualitative and quantitative study methods, inclusive of investigations, survey, secondary data and market observation.
Such plans can focus on classifying the products offered by leading market players or simply use statistical models to interpret observations or test hypotheses. While some methods aim for a detailed description of the factors behind an observation, others present the context of the current market scenario.
Now let’s take a closer look at the research methods here.
Secondary Research Model:
Extensive data is obtained and cumulated on a substantial basis during the inception phase of the research process. The data accumulated is consistently filtered through validation from the in-house database, paid sources as well reputable industry magazines. A robust research study requires an understanding of the overall value chain. Annual reports and financials of industry players are studied thoroughly to have a comprehensive idea of the market taxonomy.
Post conglomeration of the data obtained through secondary research; a validation process is initiated to verify the numbers or figures. This process is usually performed by having a detailed discussion with the industry experts.
However, we do not restrict our primary interviews only to the industry leaders. Our team covers the entire value chain while verifying the data. A significant number of raw material suppliers, local manufacturers, distributors, and stakeholders are interviewed to make our findings authentic. The current trends which include the drivers, restraints, and opportunities are also derived through the primary research process.
The market estimation is conducted by analyzing the data collected through both secondary and primary research. This process involves market breakdown, bottom-up and top- down approach.
Moreover, while forecasting the market a comprehensive statistical time series model is designed for each market. Macroeconomic indicators are considered to understand the current trends of the market. Each data point is verified by the process of data triangulation method to arrive at the final market estimates.
The penultimate process results in a holistic research report. The study equips key industry players to undertake significant strategic decisions through the findings. The report encompasses detailed market information. Graphical representations of the current market trends are also made available in order to make the study highly comprehensible for the reader.
Global Social Customer Relationship Management Market Size, Share & Trends Analysis Report By Product, By Application, And Segment Forecasts, 2018 - 2026
The Social Customer Relationship Management market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and wJuly, 2019 134 Pages MAIA RESEARCH
Cannabis Based Beverages Market Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2019 -2026
The detailed market intelligence report on the Cannabis based beverages market applies the best of both primary and secondary reseJuly, 2019 156 Pages MI Reports
Mechanized Irrigation Systems Market Size, Application, Analysis, Regional Outlook, Competitive Strategies, and Forecasts, 2019-2026
The global Mechanized Irrigation Systems market was valued at $XX million in 2018, and our analysts predict the global market size will reach $XX millJuly, 2019 120 Pages MAResearch